文献速递免疫规划传染病防控与疫情报告

TAK-021,一种灭活肠道病毒71型疫苗候选株,在人清道夫受体B2转基因小鼠中提供针对异源亚基因群的交叉保护

TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
PubMed 文献 · Vaccine · 2022-04-29

TAK-021是一种基于B2亚基因群MS87株的灭活EV71疫苗候选株,在I期临床试验中安全、耐受良好且免疫原性良好,并诱导针对异源EV71亚基因群病毒的交叉中和抗体。本研究在人清道夫受体B2转基因小鼠中评估TAK-021对B4、B5、C1、C2、C4亚基因群短期(第42天)攻击及B5、C4长期(第120天)攻击的保护效果。结果显示,TAK-021诱导>90%小鼠产生中和抗体并持续至第120天,所有接种两剂的小鼠均存活第42天攻击,>80%存活第120天攻击。

要点

  • TAK-021诱导>90%小鼠产生中和抗体,抗体持续至第120天。
  • 所有接种两剂TAK-021的小鼠均产生中和抗体并存活第42天短期攻击。
  • >80%接种两剂TAK-021的小鼠存活第120天长期攻击。

核心结论

  • 结果表明TAK-021可在小鼠中针对所测试的EV71亚基因群提供保护。

研究设计与样本

  • 在人清道夫受体B2转基因(hSCARB2-tg)小鼠中,于第0天和第28天免疫TAK-021,评估第42天(短期)对B4、B5、C1、C2、C4亚基因群攻击及第120天(长期)对B5、C4亚基因群攻击的效力。

主要发现

  • TAK-021诱导>90%的小鼠产生中和抗体(nAb),且nAb持续至第120天。
  • 对照动物攻击后出现体重减轻和死亡,以及多器官病毒检出和脑组织病理学病变。
  • 所有接种两剂TAK-021的小鼠均产生nAb并存活第42天短期攻击,>80%存活第120天长期攻击。
  • 与未免疫对照小鼠相比,免疫小鼠器官中EV71检出频率更低、水平更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enterovirus 71 (EV71) is a major cause of outbreaks of hand, foot and mouth disease, most frequently in children, and is a public health concern in the Asia-Pacific region. Takeda is developing TAK-021, an inactivated EV71 vaccine candidate based on sub-genogroup B2 strain MS87. In a phase I clinical trial, TAK-021 was safe, well tolerated, and immunogenic in healthy adults and elicited cross-neutralizing antibodies against heterologous EV71 sub-genogroup viruses. TAK-021 confers protection from lethal challenge with a mouse-adapted homologous strain in AG129 mice. However, it has not been determined whether TAK-021 can provide cross-protection against heterologous EV71 sub-genogroups. METHODS: We examined the efficacy of TAK-021 against challenge with EV71 sub-genogroups B4, B5, C1, C2, and C4 on day 42 (short-term) and sub-genogroups B5 and C4 on day 120 (long-term) after immunization of human scavenger receptor B2 transgenic (hSCARB2-tg) mice with TAK-021 on days 0 and 28. Antibody titers were monitored over 120 days using plaque reduction neutralization test of the homologous vaccine virus. RESULTS: TAK-021 elicited neutralizing antibody (nAb) in greater than 90% of the mice and nAb persisted through day 120. Challenge of control animals led to weight loss and death, as well as virus detection in various organs and histopathological lesions in the brain. All mice that received two doses of TAK-021 developed nAb and survived a short-term challenge given on day 42, while more than 80% survived a long-term challenge given on day 120. EV71 was detected less frequently and at lower levels in organs of immunized mice compared to non-immunized control mice. CONCLUSIONS: The results show that TAK-021 can confer protection in mice against the EV71 sub-genogroups tested.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tamura K, Kohnoe M, Takashino A, et al. TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice. Vaccine. 2022. PMID: 35501179. doi:10.1016/j.vaccine.2022.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。